Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Astrego Diagnostics AB in conjunction with capital procurement
Mandate

Vinge advises Astrego Diagnostics AB in conjunction with capital procurement

January 29, 2020 M&A

Vinge has advised Astrego Diagnostics AB in connection with the investment in the company by the Japanese company Sysmex Corporation, which has acquired approximately 25% of the shares in the company.

Astrego develops a ground‑breaking technology for characterization of antibiotic‑sensitivity. The first product gives doctors a patient specific diagnostic tool for urinary infections.

Vinge’s team consisted of Johan Winnerblad, Kristina Ekberg and Viktoria Owetz Leyva.

Related

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026

Vinge has advised Skeptiva AB in connection with its financing round

 Skeptiva is developing the next generation of cybersecurity defenses against fraud. The company has developed an AI application that detects attacks and alerts users in real time.
March 11, 2026

Vinge has advised Main Capital in connection with the acquisition of Good Solutions Sweden AB

 Good Solutions Sweden AB (”Good Solutions”) provides software that helps factories identify and reduce production losses. The software converts data from machines and operators into insights that can be used to streamline production and increase profitability.
March 11, 2026